Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Other Accumulated Expenses: 2014-2020

Historic Other Accumulated Expenses for AC Immune (ACIU) over the last 4 years, with Jun 2020 value amounting to $202.4 million.

  • AC Immune's Other Accumulated Expenses fell 33.69% to $202.4 million in Q2 2020 from the same period last year, while for Jun 2020 it was $202.4 million, marking a year-over-year decrease of 33.69%. This contributed to the annual value of $355,655 for FY2019, which is N/A change from last year.
  • AC Immune's Other Accumulated Expenses amounted to $202.4 million in Q2 2020, which was up 150,475.32% from $134,400 recorded in Q1 2020.
  • AC Immune's 5-year Other Accumulated Expenses high stood at $305.2 million for Q2 2019, and its period low was -$709,484 during Q2 2017.
  • In the last 3 years, AC Immune's Other Accumulated Expenses had a median value of $371,472 in 2019 and averaged $56.7 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first slumped by 353.09% in 2017, then skyrocketed by 53,065.25% in 2019.
  • Quarterly analysis of 5 years shows AC Immune's Other Accumulated Expenses stood at -$21,001 in 2016, then grew by 29.30% to $1.5 million in 2017, then crashed by 44.03% to $848,685 in 2018, then slumped by 56.23% to $355,655 in 2019, then slumped by 33.69% to $202.4 million in 2020.
  • Its Other Accumulated Expenses was $202.4 million in Q2 2020, compared to $134,400 in Q1 2020 and $355,655 in Q4 2019.